Vaderis Announces Acceptance of Abstract on VAD044 Proof-of-Concept Clinical Trial in Hereditary Hemorrhagic Telangiectasia for Oral Presentation at the 2024 ASH Annual Meeting
Basel, Switzerland. November 5th, 2024
Basel, Switzerland. November 5th, 2024 – Vaderis Therapeutics AG (Vaderis), a clinical stage biotechnology company focused on developing treatments for rare diseases associated with vascular malformations, today announces an abstract on its medicinal drug candidate VAD044 has been accepted for oral presentation at the 66th ASH Annual Meeting and Exposition taking place December 7-10, 2024, in San Diego, California.
Abstract Title
Date / Time / Presenter
Session Name / Location
A Randomized, Placebo-Controlled, Multicenter Proof-of-Concept (POC) Study to Assess the Safety and Efficacy of the Novel Allosteric AKT Inhibitor, VAD044, in Adults with Hereditary Hemorrhagic Telangiectasia (HHT)
Sunday December 8, 2024, 12 pm
Dr. Hanny Al-Samkari, the Peggy S. Blitz Endowed Chair in Hematology / Oncology at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School
Session: 323.
Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Novel Treatments and Outcomes
The abstract is available online at the 66th ASH Annual Meeting and Exposition.
For further information please contact:
Vaderis Therapeutics AG
Nicholas Benedict